Biography

Dr. Violin co-founded Dianthus in July 2019 and has served on the Board of Directors since. Dr. Violin has served as a Venture Partner at Fairmount Funds Management LLC (“Fairmount”), a healthcare investment firm, since June 2023, and as President, Interim CEO, and member of the Board of Directors of Crescent BioPharma, Inc. since October 2024. Prior to joining Fairmount, he was the President and Chief Executive Officer of Viridian Therapeutics, Inc., which he also co-founded, and is an accomplished scientist and experienced leader in drug discovery and development, and in scientific platform development. He previously served as founding Chief Executive Officer of Quellis Biosciences, which was acquired by Astria Therapeutics, Inc. in 2018, and served on the Astria Therapeutics board of directors from January 2021 until it’s acquisition by BioCryst Pharmaceuticals in January 2026. Prior to that, Dr. Violin co-founded and helped lead Trevena Inc. from discovery research through clinical development and NDA submission, including multiple rounds of venture and public financing. Dr. Violin holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, an M.B.A. with a concentration in Health Sector Management from the Fuqua School of Business, and a B.S. in Chemical Pharmacology from Duke University.